Clinical Trial

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics of VX-828 and VX-828 in triple combination (TC) with Tezacaftor (TEZ)/ VX-118 or TEZ/ deutivacaftor (D-IVA) in healthy participants and VX-828 in combination with D-IVA with or without TEZ in participants with cystic fibrosis (CF).
Protocol Amendment History 5 changes
critical Trial completed 2026-08-11
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-27
notable Enrollment reduced: 255 -> 165 participants 2026-05-27
notable Primary completion pushed: 2026-04-23 -> 2026-07-16 2026-05-27
minor Completion pushed: 2026-04-23 -> 2026-07-16 2026-05-27
Trial Details
NCT Number NCT06154447
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Cystic Fibrosis
Enrollment 165 participants
Start Date 2023-12-12
Primary Completion 2026-07-10 (estimated)
Study Completion 2026-07-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-10